EHR

KNOBLOCH Information Group, BEN, and Skye Inteligencia LATAM Form Skye Salud to Modernize Healthcare in Mexico with Sovereign AI

WILMINGTON, Del. and MEXICO CITY, Dec. 11, 2025 /PRNewswire/ -- Brand Engagement Network, Inc. (Nasdaq: BNAI) ("BEN"), a developer of…

2 weeks ago

Ritten Announces $35M Series B Investment Led by Five Elms Capital

PHILADELPHIA, Dec. 11, 2025 /PRNewswire/ -- Ritten, a leading AI-powered system of record for behavioral health providers, today announced a $35…

2 weeks ago

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease Results show, for…

2 weeks ago

SkinSight™ AI by ModuleMD: Smarter Skin Analysis, Faster Clinical Decisions

GRAND BLANC, Mich., Dec. 10, 2025 /PRNewswire/ -- ModuleMD, ranked as one of America's fastest-growing companies on the Inc. 5000…

2 weeks ago

Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration

MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”)…

2 weeks ago

Telix and Varian Announce Strategic Theranostics-EBRT Clinical Collaboration

MELBOURNE, Australia and PALO ALTO, Calif., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”)…

2 weeks ago

JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…

2 weeks ago

JASCAYD® (nerandomilast) receives first regulatory approval for progressive pulmonary fibrosis in China

The approval marks the first new treatment option for people living with progressive pulmonary fibrosis (PPF) in more than five…

2 weeks ago

Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targetsThe agreement -…

2 weeks ago

Oxford BioTherapeutics Enters into a Strategic Collaboration with GSK to Discover Novel Targets for Antibody-Based Therapeutics for the Treatment of Cancer

Collaboration leverages OBT's proprietary OGAP®-Verify platform and GSK's drug development expertise to advance multiple selected novel oncology targetsThe agreement -…

2 weeks ago